



## Curriculum Vitae

Personal information Evangelos Manolopoulos

Work experience

---

### CURRENT POSITIONS

- 2014-today** **Professor of Pharmacology, Pharmacogenomics & Precision Medicine** Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, Alexandroupolis, Greece
- 11/2023-today** **President of Greek National Organization for Medicines**, Athens, Greece

### PREVIOUS POSITIONS

- 05/03 - 09/08 & 06/17 – 08/23: Director**, Laboratory of Pharmacology, Medical Department, Democritus University of Thrace, Alexandroupolis, Greece
- 08/02 – 09/08 & 06/17 - σήμερα: Director**, Clinical Pharmacology Unit, Academic General Hospital of Evros, Alexandroupolis, Greece
- 04/09 – 12/13** **Associate Professor**, DUTH, Medical Department, Lab. of Pharmacology
- 04/03 - 04/09: Assistant Professor**, DUTH, Medical Department, Lab. of Pharmacology
- 12/98 - 04/03: Lecturer**, DUTH, Medical Department, Lab. of Pharmacology
- 01/98 - 11/98: Visitor Researcher**, Katholieke Universiteit Leuven, Laboratory of Physiology, Medical School, Leuven, Belgium
- 07/97 - 11/97: Researcher**, Department of Research in Biomedicines, 251 General Air Force Hospital, Athens
- 09/95 - 02/97: Postdoctoral Researcher**, Katholieke Universiteit Leuven, Laboratory of Pharmacology, Medical School, Leuven, Belgium
- 01/92 - 08/95: Postdoctoral Researcher**, University of Wisconsin, Laboratory of Cell Biology, Medical School, Medical Campus at Mt. Sinai Hospital, Milwaukee, Wisconsin, USA
- 10/89 - 07/90: Visitor Researcher**, University of Groningen,

Laboratory of Clinical Pharmacology, Medical School,  
Groningen, The Netherlands

**11/86 - 12/91: Postgraduate Student**, University of Patras, Laboratory  
of Pharmacology, Faculty of Medicine, Patras, Greece

**01/85 - 10/86: Assistant Researcher**, University of Patras, Biology  
Department, Laboratory of Embryology, Patras, Greece

## Education and training

---

**10/1986 - 02/1992** Pharmacology Ph.D, Medical School, Patras  
University, Greece

**10/1979 - 10/ 1984** Biology B.Sc, School of Health Sciences, Patras  
University, Greece

**09/ 1973 - 06/1979** Secondary education, Lycée Léonin, Athens, Greece

## Additional information

---

### Publications

### LIST OF PUBLICATIONS IN PUBMED

1. Atzemian N, Kareli D, Ragia G, Manolopoulos VG. Distinctive pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: A comprehensive review. *Frontiers in Pharmacology* 2023; 14:1244098. doi: 10.3389/fphar.2023.1244098.
2. Ragia G, Maslarinou A, Atzemian N, Biziota E, Koukaki T, Ioannou C, Balgkouranidou I, Kolios G, Kakolyris S, Xenidis N, Amarantidis K, Manolopoulos VG. Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece. *Frontiers in Pharmacology* 2023; 14:1248898. doi: 10.3389/fphar.2023.1248898.
3. Voulgaridou G, Paraskeva T, Ragia G, Atzemian N, Portokallidou K, Kolios G, Arvanitidis K, Manolopoulos VG. Therapeutic drug monitoring (TDM) implementation in public hospitals in Greece in 2003 and 2021: a comparative analysis of TDM evolution over the years. *Pharmaceutics* 2023; 15:2181. doi: 10.3390/pharmaceutics15092181.
4. Spathakis M, Tarapatzi G, Filidou E, Kandilogiannakis L, Karatzas E, Steiropoulos P, Mikroulis D, Spyrou GM, Manolopoulos VG, Kolios G, Arvanitidis K. Niclosamide Attenuates Inflammation-Associated Profibrotic Responses in Human Subepithelial Lung Myofibroblasts. *Biomedicines*. 2023 Jul 19;11(7):2032. doi: 10.3390/biomedicines11072032. PMID: 37509671
5. Maslarinou A, Manolopoulos VG, Ragia G. Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm? *Front Pharmacol*. 2023 May 15;14:1184523. doi: 10.3389/fphar.2023.1184523. PMID: 37256234
6. Panagiotou D, Filidou E, Gaitanidou M, Tarapatzi G, Spathakis M,

- Kandilogiannakis L, Stavrou G, Arvanitidis K, Tsetis JK, Gionga P, Shrewsbury AD, Manolopoulos VG, Kapoukranidou D, Lasithiotakis K, Kolios G, Kotzampassi K. Role of Lactiplantibacillus plantarum UBLP-40, Lactobacillus rhamnosus UBLR-58 and Bifidobacterium longum UBBL-64 in the Wound Healing Process of the Excisional Skin. *Nutrients*. 2023 Apr 10;15(8):1822. doi: 10.3390/nu15081822. PMID: 37111041
7. van Schaik RH, Manolopoulos VG, Daly AK, Niemi M, Zukic B, Patrinos GP, Primorac D, Swen JJ, Ingelman-Sundberg M, Morris T, Molden E, Müller D, Pavlovic S, Russmann S, Ansari M, Henricks LM, den Broek WV, Florindi F, Bozina N, Akin D, Christrup L, Llerena A, Sipeky C, Stankovic S. The Sixth European Society of Pharmacogenomics and Personalised Therapy Congress. *Pharmacogenomics*. 2023 Apr;24(5):243-246. doi: 10.2217/pgs-2023-0013. PMID: 37014361
8. Portokallidou K, Dovrolis N, Ragia G, Atzemian N, Kolios G, Manolopoulos VG. [Multi-omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy](#). *Front Cardiovasc Med*. 2023 Feb 13;10:1115623. doi: 10.3389/fcvm.2023.1115623. PMID: 36860278
9. Dovrolis N, Filidou E, Tarapatzi G, Kokkotis G, Spathakis M, Kandilogiannakis L, Drygiannakis I, Valatas V, Arvanitidis K, Karakasiliotis I, Vradelis S, Manolopoulos VG, Paspaliaris V, Bamias G, Kolios G. [Co-expression of fibrotic genes in inflammatory bowel disease: A localized event?](#) *Front Immunol*. 2022 Dec 23;13:1058237. doi: 10.3389/fimmu.2022.1058237. PMID: 36632136
10. Tarapatzi G, Filidou E, Kandilogiannakis L, Spathakis M, Gaitanidou M, Arvanitidis K, Drygiannakis I, Valatas V, Kotzampassi K, Manolopoulos VG, Kolios G, Vradelis S. [The Probiotic Strains Bifidobacterium lactis, Lactobacillus acidophilus, Lactiplantibacillus plantarum and Saccharomyces boulardii Regulate Wound Healing and Chemokine Responses in Human Intestinal Subepithelial Myofibroblasts](#). *Pharmaceuticals (Basel)*. 2022 Oct 20;15(10):1293. doi: 10.3390/ph15101293. PMID: 36297405
11. Ragia G, Manolopoulos VG. [The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?](#) *Pharmacogenomics*. 2022 Nov;23(16):869-872. doi: 10.2217/pgs-2022-0145. PMID: 36285650
12. Anatolou D, Dovrolis N, Ragia G, Kolios G, Manolopoulos VG. [Unpacking COVID-19 Systems Biology in Lung and Whole Blood with Transcriptomics and miRNA Regulators](#). *OMICS*. 2022 Nov;26(11):608-621. doi: 10.1089/omi.2022.0104. PMID: 36269619

13. Deligiannidou GE, Kyrgou C, Nena E, Manolopoulos VG, Bezirtzoglou E, Kontogiorgis CA, Constantinidis TC. [Use of Edible, Medicinal, and Aromatic Plants in Various Health Disorders: A Cross-Sectional Evaluation among Inhabitants in the Area of Thrace, North-Eastern Greece](#). *Int J Environ Res Public Health*. 2022 Oct 1;19(19):12576. doi: 10.3390/ijerph191912576. PMID: 36231876
14. Ragia G, Atzemia N, Maslarinou A, Manolopoulos VG. [SLCO1B1 c.521T>C gene polymorphism decreases hypoglycemia risk in sulfonylurea-treated type 2 diabetic patients](#). *Drug Metab Pers Ther*. 2022 Sep 28;37(4):347-352. doi: 10.1515/dmpt-2022-0131. PMID: 36169244
15. Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, Biziota E, Kakolyris S, Manolopoulos VG. [MTHFR c.665C>T guided fluoropyrimidine therapy in cancer: gender-dependent effect on dose requirements](#). *Drug Metab Pers Ther*. 2022 Mar 11;37(3):323-327. doi: 10.1515/dmpt-2021-0219. PMID: 35272420
16. Taron M, Llerena A, Manolopoulos VG, Rodriguez-Antona C, Stankovic S, van Schaik RHN. The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. *Drug Metab Pers Ther*. 2020 Nov 13;35(4). doi: 10.1515/dmpt-2020-0172. PMID: 34704693
17. Roumeliotis S, Georgianos PI, Roumeliotis A, Eleftheriadis T, Stamou A, Manolopoulos VG, Panagoutsos S, Liakopoulos V. Oxidized LDL Modifies the Association between Proteinuria and Deterioration of Kidney Function in Proteinuric Diabetic Kidney Disease. *Life (Basel)*. 2021 May 29;11(6):504. doi:10.3390/life11060504. PMID: 34072583.
18. Roumeliotis S, Roumeliotis A, Stamou A, Panagoutsos S, Manolopoulos VG, Tsetsos F, Georgitsi M, Liakopoulos V. Association of rs11780592 Polymorphism in the Human Soluble Epoxide Hydrolase Gene (EPHX2) with Oxidized LDL and Mortality in Patients with Diabetic Chronic Kidney Disease. *Oxid Med Cell Longev*. 2021 May 6;2021:8817502. doi: 10.1155/2021/8817502. PMID: 34040693.
19. Panagopoulou M, Karaglani M, Manolopoulos VG, Iliopoulos I, Tsamardinos I, Chatzaki E. Deciphering the Methylation Landscape in Breast Cancer: Diagnostic and Prognostic Biosignatures through Automated Machine Learning. *Cancers (Basel)*. 2021 Apr 2;13(7):1677. doi: 10.3390/cancers13071677. PMID: 33918195.
20. Ragia G, Katsika E, Ioannou C, Manolopoulos VG. TCF7L2 rs7903146 C>T gene polymorphism is not associated with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. *Drug Metab Pers Ther*. 2020 Dec 24. doi:10.1515/dmdi-2020-0168. PMID: 33780196.

21. Ragia G, Manolopoulos VG. Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry. *Pharmacogenomics*. 2020 Dec;21(18):1311-1329. doi: 10.2217/pgs-2020-0092. Epub 2020 Nov 27. PMID: 33243086; PMCID: PMC7694444.
22. Taron M, Llerena A, Manolopoulos VG, Rodriguez-Antona C, Stankovic S, van Schaik RHN. The need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients. *Drug Metab Pers Ther*. 2020 Nov 13. doi:10.1515/dmdi-2020-0172. PMID: 33185569.
23. Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. *Eur J Clin Pharmacol*. 2020 Dec;76(12):1623-1630. doi: 10.1007/s00228-020-02963-4. Epub 2020 Jul 21. PMID: 32696234; PMCID: PMC7372205.
24. Ragia G, Manolopoulos VG. Pharmacogenomics of anticoagulation therapy: the last 10 years. *Pharmacogenomics*. 2019 Nov;20(16):1113-1117. doi:10.2217/pgs-2019-0149. PMID: 31755368.
25. Sipeky C, Llerena A, Manolopoulos VG, Pearson E, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, van Schaik RH. 4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation. *Pharmacogenomics*. 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095. PMID: 31588876.
26. Karas Kuželički N, Prodan Žitnik I, Gurwitz D, Llerena A, Cascorbi I, Siest S, Simmaco M, Ansari M, Pazzagli M, Di Resta C, Brandslund I, Schwab M, Vermeersch P, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Stingl JC, van Schaik RH, Manolopoulos VG, Marc J; Pharmacogenomics Education Working Group (PGxEWG); European Society of Pharmacogenomics and Personalized Therapy (ESPT). Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey. *Pharmacogenomics*. 2019 Jun;20(9):643-657. doi:10.2217/pgs-2019-0009. PMID: 31250730.
27. Mlakar V, Marc J, Manolopoulos VG, Cascorbi I, Stanković S, Llerena A, Simmaco M, Visvikis-Siest S, Amstutz U, Sipeky C, Meyer UA, Meier-Abt P, van Schaik RH, Ansari M. 4th ESPT summer school: precision medicine and personalized health. *Pharmacogenomics*. 2019 May;20(7):471-474. doi: 10.2217/pgs-2019-0008. PMID:

31124416.

28. Coleman JJ, Samer C, Zeitlinger M, van Agtmael M, Rongen GA, Marquet P, Simon T, Singer D, Manolopoulos VG, Böttiger Y. The European Association for Clinical Pharmacology and Therapeutics- 25 years' young and going strong. *Eur J Clin Pharmacol*. 2019 Jun;75(6):743-750. doi: 10.1007/s00228-019-02690-5. PMID: 31093706.
29. Giannakopoulou E, Konstantinou F, Ragia G, Gerontitis Z, Tavridou A, Papapetropoulos A, Mikroulis D, Manolopoulos VG. Association study of the CTH 1364 G>T polymorphism with coronary artery disease in the Greek population. *Drug Metab Pers Ther*. 2019 Mar 12;34(1). doi: 10.1515/dmpt-2018-0033. PMID: 30860977.
30. Ragia G, Archontogeorgis K, Simmaco M, Gentile G, Borro M, Zissimopoulos A, Froudarakis M, Manolopoulos VG, Steiropoulos P. Genetics of Obstructive Sleep Apnea: Vitamin D Receptor Gene Variation Affects Both Vitamin D Serum Concentration and Disease Susceptibility. *OMICS*. 2019 Jan;23(1):45-53. doi:10.1089/omi.2018.0184. PMID: 30562127.
31. Archontogeorgis K, Nena E, Papanas N, Rizzo M, Voulgaris A, Xanthoudaki M, Kouratzi M, Ragia G, Manolopoulos V, Zissimopoulos A, Froudarakis M, Steiropoulos P. Metabolic Syndrome and Vitamin D Levels in Patients with Obstructive Sleep Apnea Syndrome. *Metab Syndr Relat Disord*. 2018 May;16(4):190-196. doi: 10.1089/met.2017.0181. PMID: 29608396.
32. Kalinderi K, Asimakopoulos B, Nikolettos N, Manolopoulos VG. Pharmacogenomics in IVF: A New Era in the Concept of Personalized Medicine. *Reprod Sci*. 2019 Oct;26(10):1313-1325. doi: 10.1177/1933719118765970. PMID: 29587614.
33. Ragia G, Manolopoulos VG. From Homer and Hippocrates to modern personalized medicine: is there a role for pharmacoepigenomics in the treatment of alcohol addiction? *Pharmacogenomics*. 2018 Apr;19(6):513-516. doi: 10.2217/pgs-2018-0025. PMID: 29580163.
34. Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, Papanas N, Manolopoulos VG, Chatzaki E. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment. *Exp Clin Endocrinol Diabetes*. 2019 Apr;127(4):226-233. doi: 10.1055/s-0043-121265. Epub 2018 Feb 2. PMID: 29396966.
35. Ragia G, Karantza IM, Kelli-Kota E, Kolovou V, Kolovou G, Konstantinides S, Maltezos E, Tavridou A, Tziakas D, Maitland-van der Zee AH, Manolopoulos VG. Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis.

Drug Metab Pers Ther. 2017 Dec 20;32(4):183-190. doi:10.1515/dmpt-2017-0034. PMID: 29252193.

36. Roumeliotis AK, Roumeliotis SK, Panagoutsos SA, Tsetsos F, Georgitsi M, Manolopoulos V, Paschou P, Passadakis PS. Association of ALOX12 gene polymorphism with all-cause and cardiovascular mortality in diabetic nephropathy. *Int Urol Nephrol*. 2018 Feb;50(2):321-329. doi:10.1007/s11255-017-1755-z. Epub 2017 Dec 1. PMID: 29196930.
37. Giannakopoulou E, Konstantinou F, Ragia G, Tavridou A, Karaglani M, Chatzaki E, Papapetropoulos A, Mikroulis D, Manolopoulos VG. Epigenetics-by-Sex Interaction for Coronary Artery Disease Risk Conferred by the Cystathionine  $\gamma$ -Lyase Gene Promoter Methylation. *OMICS*. 2017 Dec;21(12):741-748. doi:10.1089/omi.2017.0149. Epub 2017 Nov 27. PMID: 29173085.
38. Roumeliotis S, Roumeliotis A, Panagoutsos S, Giannakopoulou E, Papanas N, Manolopoulos VG, Passadakis P, Tavridou A. Matrix Gla protein T-138C polymorphism is associated with carotid intima media thickness and predicts mortality in patients with diabetic nephropathy. *J Diabetes Complications*. 2017 Oct;31(10):1527-1532. doi: 10.1016/j.jdiacomp.2017.06.012. PMID: 28734846.
39. Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Celedón JC, Chew FT, Chiang WC, Cloutier MM, Daley D, Den Dekker HT, Dijk FN, Duijts L, Flores C, Forno E, Hawcutt DB, Hernandez-Pacheco N, de Jongste JC, Kabesch M, Koppelman GH, Manolopoulos VG, Melén E, Mukhopadhyay S, Nilsson S, Palmer CN, Pino-Yanes M, Pirmohamed M, Potočník U, Raaijmakers JA, Repnik K, Schieck M, Sio YY, Smyth RL, Szalai C, Tantisira KG, Turner S, van der Schee MP, Verhamme KM, Maitland-van der Zee AH. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. *Pharmacogenomics*. 2017 Jul;18(10):931-943. doi: 10.2217/pgs-2017-0035. PMID:28639505; PMCID: PMC5967359.
40. Archontogeorgis K, Nena E, Papanas N, Zissimopoulos A, Voulgaris A, Xanthoudaki M, Manolopoulos V, Froudarakis M, Steiropoulos P. Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome. *Curr Vasc Pharmacol*. 2018;16(3):289-297. doi: 10.2174/1570161115666170529085708. PMID: 28552071.
41. Ragia G, Manolopoulos VG. Personalized Medicine of Alcohol Addiction: Pharmacogenomics and Beyond. *Curr Pharm Biotechnol*. 2017;18(3):221-230. doi: 10.2174/1389201018666170224105025. PMID: 28240173.

42. Baranova EV, Verhoef TI, Ragia G, le Cessie S, Asselbergs FW, de Boer A, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. *J Thromb Haemost.* 2017 Mar;15(3):465-472. doi: 10.1111/jth.13615. Epub 2017 Feb 17. PMID: 28063245.
43. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT group. Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. *J Thromb Haemost.* 2017 Mar;15(3):454-464. doi: 10.1111/jth.13601. PMID:27992949.
44. Ragia G, Kolovou V, Kolovou G, Konstantinides S, Maltezos E, Tavridou A, Tziakas D, Maitland-van der Zee AH, Manolopoulos VG. A novel acenocoumarol pharmacogenomic dosing algorithm for the Greek population of EU-PACT trial. *Pharmacogenomics.* 2017 Jan;18(1):23-34. doi: 10.2217/pgs-2016-0126. PMID: 27967328.
45. Ragia G, Veresies I, Veresie L, Veresies K, Manolopoulos VG. Association study of DRD2 A2/A1, DRD3 Ser9Gly, D $\beta$ H -1021C>T, OPRM1 A118G and GRIK1 rs2832407C>A polymorphisms with alcohol dependence. *Drug Metab Pers Ther.* 2016 Sep 1;31(3):143-50. doi: 10.1515/dmpt-2016-0015. PMID: 27447243.
46. Iordanidou M, Paraskakis E, Tavridou A, Chatzimichael A, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms are associated with sensitization to seasonal aeroallergens in asthmatic children. *World J Pediatr.* 2017 Feb;13(1):34-40. doi: 10.1007/s12519-016-0043-9. PMID:27363984.
47. Chatzianastasiou A, Bibli SI, Andreadou I, Efentakis P, Kaludercic N, Wood ME, Whiteman M, Di Lisa F, Daiber A, Manolopoulos VG, Szabó C, Papapetropoulos A. Cardioprotection by H<sub>2</sub>S Donors: Nitric Oxide-Dependent and -Independent Mechanisms. *J Pharmacol Exp Ther.* 2016 Sep;358(3):431-40. doi: 10.1124/jpet.116.235119. PMID: 27342567; PMCID: PMC6047225.
48. Ragia G, Dahl ML, Manolopoulos VG. Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs. *Curr Drug Metab.* 2016;17(3):227-36. doi:10.2174/1389200217666151210125831. PMID: 26651976.
49. Siest G, Auffray C, Taniguchi N, Ingelman-Sundberg M, Murray H, Visvikis-Siest S, Ansari M, Marc J, Jacobs P, Meyer U, Van Schaik RH, Müller MM, Wevers RA, Simmaco M, Kussmann M, Manolopoulos VG, Alizadeh BZ, Beastall G, Németh G. Systems medicine, personalized health and therapy. *Pharmacogenomics.* 2015;16(14):1527-39. doi: 10.2217/pgs.15.103. PMID: 26401575.



50. Kolovou G, Kolovou V, Ragia G, Mihas C, Diakoumakou O, Vasiliadis I, Mavrogeni S, Vartela V, Manolopoulos VG. CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. *Genet Mol Biol.* 2015 May;38(2):129-37. doi: 10.1590/S1415-4757382220140239. PMID: 26273214.
51. Belley-Cote EP, Hanif H, D'Aragnon F, Eikelboom JW, Anderson JL, Borgman M, Jonas DE, Kimmel SE, Manolopoulos VG, Baranova E, Maitland-van der Zee AH, Pirmohamed M, Whitlock RP. Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. *Thromb Haemost.* 2015 Oct;114(4):768-77. doi:10.1160/TH15-01-0071. PMID: 26158747.
52. Tavridou A, Georgoulidou A, Roumeliotis A, Roumeliotis S, Giannakopoulou E, Papanas N, Passadakis P, Manolopoulos VG, Vargemezis V. Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy. *J Diabetes Res.* 2015;2015:507265. doi:10.1155/2015/507265. Epub 2015 May 12. PMID: 26064982; PMCID: PMC4443755.
53. Zhang Y, de Boer A, Verhoef TI, van der Meer FJ, Le Cessie S, Maitland-van der Zee AH; EU-PACT group; members of the EU-PACT group are. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. *Thromb Res.* 2015 Jul;136(1):94-100. doi: 10.1016/j.thromres.2015.04.034. Epub 2015 May 2. PMID: 25971661.
54. Marvig CL, Verhoef TI, de Boer A, Kamali F, Redekop K, Pirmohamed M, Daly AK, Manolopoulos VG, Wadelius M, Bouvy M, Maitland-van der Zee AH; EU-PACT consortium. Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. *Thromb Res.* 2015 Jul;136(1):69-75. doi: 10.1016/j.thromres.2015.04.026. PMID:25956287.
55. Misailidis G, Ragia G, Ivanova DD, Tavridou A, Manolopoulos VG. Gene-gene interaction of  $\mu$ -opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. *Drug Metab Pers Ther.* 2015 Jun;30(2):129-35. doi:10.1515/dmdi-2015-0005. PMID: 25941919.
56. Drogari E, Ragia G, Mollaki V, Elens L, Van Schaik RH, Manolopoulos VG. POR\*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. *Pharmacogenomics.* 2014 Dec;15(16):1963-72. doi: 10.2217/pgs.14.138. PMID: 25521355.
57. Iordanidou M, Paraskakis E, Giannakopoulou E, Tavridou A, Gentile G, Borro M, Simmaco M, Chatzimichael A, Bush A, Manolopoulos VG.

Vitamin D receptor ApaI a allele is associated with better childhood asthma control and improvement in ability for daily activities. *OMICS*. 2014 Nov;18(11):673-81. doi: 10.1089/omi.2014.0023. PMID: 25353337.

58. Knappskog S, Gansmo LB, Dibirova K, Metspalu A, Cybulski C, Peterlongo P, Aaltonen L, Vatten L, Romundstad P, Hveem K, Devilee P, Evans GD, Lin D, Van Camp G, Manolopoulos VG, Osorio A, Milani L, Ozcelik T, Zalloua P, Mouzaya F, Bliznetz E, Balanovska E, Pocheshkova E, Kučinskas V, Atramentova L, Nymadawa P, Titov K, Lavryashina M, Yusupov Y, Bogdanova N, Koshel S, Zamora J, Wedge DC, Charlesworth D, Dörk T, Balanovsky O, Lønning PE. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). *Oncotarget*. 2014 Sep 30;5(18):8223-34. doi: 10.18632/oncotarget.1910. PMID: 25327560.
59. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4\*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. *Drug Metab Pers Ther*. 2015 Mar;30(1):43-8. doi:10.1515/dmdi-2014-0021. PMID: 25274942.
60. Hekim N, Coşkun Y, Sınay A, Abou-Zeid AH, Ağırbaşlı M, Akintola SO, Aynacıoğlu Ş, Bayram M, Bragazzi NL, Dandara C, Dereli T, Dove ES, Elbeyli L, Endrenyi L, Erciyas K, Faris J, Ferguson LR, Göğüş F, Güngör K, Gürsoy M, Gürsoy UK, Karaömerlioğlu MA, Kickbusch I, Kılıç T, Kılınç M, Kocagöz T, Lin B, Llerena A, Manolopoulos VG, Nair B, Özkan B, Pang T, Sardaş Ş, Srivastava S, Toraman C, Üstün K, Warnich L, Wonkam A, Yakıcıer MC, Yaşar Ü, Özdemir V. Translating biotechnology to knowledge-based innovation, peace, and development? Deploy a Science Peace Corps--an open letter to world leaders. *OMICS*. 2014 Jul;18(7):415-20. doi: 10.1089/omi.2014.0079. PMID: 24955641.
61. Maitland-van der Zee AH, de Boer A, Manolopoulos VG; EU-PACT Group. Genotype-guided dosing of vitamin K antagonists. *N Engl J Med*. 2014 May 1;370(18):1765-6. doi: 10.1056/NEJMc1402521. PMID: 24804306.
62. Ragia G, Giannakopoulou E, Karaglani M, Karantza IM, Tavridou A, Manolopoulos VG. Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance. *Drug Metabol Drug Interact*. 2014;29(4):235-48. doi: 10.1515/dmdi-2014-0006. PMID: 24756055.

63. Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G, Manolopoulos VG. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. *Mol Biol Rep*. 2014 Jul;41(7):4631-8. doi: 10.1007/s11033-014-3334-z. PMID: 24668570.
64. Kolovou G, Ragia G, Kolovou V, Mihas C, Katsiki N, Vasiliadis I, Mavrogeni S, Vartela V, Tavridou A, Manolopoulos VG. Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. *Open Cardiovasc Med J*. 2014 Feb 7;8:12-7. doi: 10.2174/1874192401408010012. PMID: 24653785; PMCID: PMC3959175.
65. Ragia G, Tavridou A, Elens L, Van Schaik RH, Manolopoulos VG. CYP2C9\*2 allele increases risk for hypoglycemia in POR\*1/\*1 type 2 diabetic patients treated with sulfonylureas. *Exp Clin Endocrinol Diabetes*. 2014 Jan;122(1):60-3. doi: 10.1055/s-0033-1361097. Epub 2014 Jan 24. PMID: 24464600.
66. Ragia G, Kolovou V, Tavridou A, Elens L, Tselepis AD, Elisaf M, Van Schaik RH, Kolovou G, Manolopoulos VG. Lack of association of the p450 oxidoreductase \*28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. *Mol Diagn Ther*. 2014 Jun;18(3):323-31. doi:10.1007/s40291-013-0082-z. PMID: 24430948.
67. Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A. Association of functional VKORC1 promoter polymorphism with occurrence and clinical aspects of ischemic stroke in a Greek population. *Dis Markers*. 2013;35(6):641-6. doi:10.1155/2013/769574. Epub 2013 Oct 31. PMID: 24288433; PMCID: PMC3832979.
68. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. *N Engl J Med*. 2013 Dec 12;369(24):2294-303. doi:10.1056/NEJMoa1311386. PMID: 24251363.
69. Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. *N Engl J Med*. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. PMID: 24251360.
70. Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT Group.

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. *Pharmacogenomics*. 2013 Jun;14(8):869-83. doi: 10.2217/pgs.13.74. PMID: 23746182.

71. Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. *Biomed Res Int*. 2013;2013:315980. doi: 10.1155/2013/315980. PMID: 23586031.
72. Ozdemir V, Borda-Rodriguez A, Dove ES, Ferguson LR, Huzair F, Manolopoulos VG, Masellis M, Milius D, Warnich L, Srivastava S. Public Health Pharmacogenomics and the Design Principles for Global Public Goods – Moving Genomics to Responsible Innovation. *Curr Pharmacogenomics Person Med*. 2013 Mar 24;11(1):1-4. doi: 10.2174/1875692111311010001. PMID: 23531886.
73. Staikos C, Ververidis A, Drosos G, Manolopoulos VG, Verettas DA, Tavridou A. The association of adipokine levels in plasma and synovial fluid with the severity of knee osteoarthritis. *Rheumatology (Oxford)*. 2013 Jun;52(6):1077-83. doi: 10.1093/rheumatology/kes422. PMID: 23382357.
74. Giannakopoulou E, Ragia G, Marousi S, Ellul J, Manolopoulos VG, Tavridou A. Association of monocyte chemoattractant protein-1 - 2518A>G polymorphism with occurrence, severity, and outcome in ischemic stroke. *Neurol Sci*. 2013 Aug;34(8):1315-20. doi: 10.1007/s10072-012-1235-2. PMID:23135705.
75. Stathias V, Sotiris GR, Karagiannidis I, Bourikas G, Martinis G, Papazoglou D, Tavridou A, Papanas N, Maltezos E, Theodoridis M, Vargemezis V, Manolopoulos VG, Speed WC, Kidd JR, Kidd KK, Drineas P, Paschou P. Exploring genomic structure differences and similarities between the Greek and European HapMap populations: implications for association studies. *Ann Hum Genet*. 2012 Nov;76(6):472-83. doi: 10.1111/j.1469-1809.2012.00730.x. PMID: 23061745.
77. Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland-van der Zee AH; EU-PACT group. Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. *J Thromb Haemost*. 2012 Dec;10(12):2610-2. doi: 10.1111/jth.12007. PMID: 23016521.
78. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, Haschke-Becher E, Hughes DA, Kamali F, Levin LA, Manolopoulos VG, Pirmohamed M, Siebert U, Stingl JC, Wadelius M, de Boer A, Maitland-van der Zee AH; EU-PACT group. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. *Pharmacogenomics*. 2012 Sep;13(12):1405-17. doi: 10.2217/pgs.12.124. PMID: 22966889.

79. Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichael A, Manolopoulos VG. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting  $\beta$ 2-agonists in asthmatic children. *Pharmacogenomics*. 2012 Sep;13(12):1363-72. doi: 10.2217/pgs.12.120. PMID: 22966886.
80. Manolopoulos VG, Ragia G, Alevizopoulos G. Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics. *Drug Metabol Drug Interact*. 2012 Feb 29;27(1):19-31. doi: 10.1515/dmdi-2011-0033. PMID: 22718622.
81. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. *Diabetes Res Clin Pract*. 2012 Oct;98(1):119-24. doi: 10.1016/j.diabres.2012.04.017. PMID: 22591706.
82. van Schie RM, Babajeff AM, Schalekamp T, Wessels JA, le Cessie S, de Boer A, van der Meer FJ, van Meegen E, Verhoef TI, Rosendaal FR, Maitland-van der Zee AH; EU-PACT study group. An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. *J Thromb Haemost*. 2012 May;10(5):767-72. doi:10.1111/j.1538-7836.2012.04694.x. PMID: 22409277.
83. Ragia G, Manolopoulos VG. Highlights from the latest articles in diabetes pharmacogenomics. *Pharmacogenomics*. 2012 Feb;13(3):261-4. doi:10.2217/pgs.11.182. PMID: 22304578.
84. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, Wessels JA, Van Schie RM, De Boer A, Teichert M, Visser LE, Maitland-Van Der Zee AH; EU-PACT Group. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. *J Thromb Haemost*. 2012 Apr;10(4):606-14. doi:10.1111/j.1538-7836.2012.04633.x. PMID: 22252093.
85. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Barta C, Lu RB, Zhukova OV, Kim JJ, Siniscalco M, New M, Li H, Kajuna SL, Manolopoulos VG, Speed WC, Pakstis AJ, Kidd JR, Kidd KK. A global view of the OCA2-HERC2 region and pigmentation. *Hum Genet*. 2012 May;131(5):683-96. doi: 10.1007/s00439-011-1110-x. Epub 2011 Nov 8. PMID: 22065085; PMCID: PMC3325407.
86. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F; EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. *Clin Pharmacol Ther*. 2011 Nov;90(5):701-6. doi: 10.1038/clpt.2011.186. PMID: 22012312.

87. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. *Pharmacogenomics*. 2011 Aug;12(8):1161-91. doi: 10.2217/pgs.11.65. PMID: 21843065.
88. Tavridou A, Petridis I, Vasileiadis M, Ragia G, Heliopoulos I, Vargemezis V, Manolopoulos VG. Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. *Diabetes Res Clin Pract*. 2011 Nov;94(2):236-41. doi: 10.1016/j.diabres.2011.06.021. PMID: 21767890.
89. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, Verhoef TI, van Meegen E, Rosendaal FR, Maitland-van der Zee AH; EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. *Eur Heart J*. 2011 Aug;32(15):1909-17. doi: 10.1093/eurheartj/ehr116. Epub 2011 Jun 2. Erratum in: *Eur Heart J*. 2013 Jun;34(24):1854. PMID: 21636598.
90. Manolopoulos VG, Dechairo B, Huriez A, Kühn A, Llerena A, van Schaik RH, Yeo KT, Ragia G, Siest G. Pharmacogenomics and personalized medicine in clinical practice. *Pharmacogenomics*. 2011 May;12(5):597-610. doi: 10.2217/pgs.11.14. PMID: 21619425.
91. Tavridou A, Ragia G, Manolopoulos VG. Emerging targets for the treatment of dyslipidemia. *Curr Med Chem*. 2011;18(6):909-22. doi: 10.2174/092986711794927757. PMID: 21182475.
92. Ragia G, Nikolaidis E, Tavridou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, Manolopoulos VG. Endothelial nitric oxide synthase gene polymorphisms -786T > C and 894G > T in coronary artery bypass graft surgery patients. *Hum Genomics*. 2010 Aug;4(6):375-83. doi: 10.1186/1479-7364-4-6-375. PMID: 20846926.
93. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Del Zompo M, Patrinos GP. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. *Pharmacogenomics*. 2010 Aug;11(8):1149-67. doi: 10.2217/pgs.10.97. PMID: 20712531.
94. Tavridou A, Efthimiadis A, Efthimiadis I, Manolopoulos VG. Simvastatin-induced changes in circulating oxidized low-density lipoprotein in different types of dyslipidemia. *Heart Vessels*. 2010 Jul;25(4):288-93. doi: 10.1007/s00380-009-1202-x. PMID: 20676836.
95. Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A,

- Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M; EU-PACT Group. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. *Pharmacogenomics*. 2010 Jul;11(7):989-1002. doi: 10.2217/pgs.10.74. PMID:20602617.
96. Manolopoulos VG, Ragia G, Tavidou A. Pharmacogenetics of coumarinic oral anticoagulants. *Pharmacogenomics*. 2010 Apr;11(4):493-6. doi: 10.2217/pgs.10.31. PMID: 20350128.
97. Ragia G, Nikolaidis E, Tavidou A, Arvanitidis KI, Kanoni S, Dedoussis GV, Bougioukas G, Manolopoulos VG. Renin-angiotensin-aldosterone system gene polymorphisms in coronary artery bypass graft surgery patients. *J Renin Angiotensin Aldosterone Syst*. 2010 Jun;11(2):136-45. doi: 10.1177/1470320310361742. PMID: 20223792.
98. Donnelly MP, Paschou P, Grigorenko E, Gurwitz D, Mehdi SQ, Kajuna SL, Barta C, Kungulilo S, Karoma NJ, Lu RB, Zhukova OV, Kim JJ, Comas D, Siniscalco M, New M, Li P, Li H, Manolopoulos VG, Speed WC, Rajeevan H, Pakstis AJ, Kidd JR, Kidd KK. The distribution and most recent common ancestor of the 17q21 inversion in humans. *Am J Hum Genet*. 2010 Feb 12;86(2):161-71. doi: 10.1016/j.ajhg.2010.01.007. PMID: 20116045.
99. Iordanidou M, Tavidou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, Manolopoulos VG. Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. *Drug Alcohol Depend*. 2010 Apr 1;108(1-2):70-6. doi: 10.1016/j.drugalcdep.2009.11.015. PMID: 20060656.
100. Iordanidou M, Tavidou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG. The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. *Clin Chim Acta*. 2010 Feb;411(3-4):167-71. doi: 10.1016/j.cca.2009.10.022. PMID:19891962.
101. Ragia G, Petridis I, Tavidou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9\*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. *Pharmacogenomics*. 2009 Nov;10(11):1781-7. doi:10.2217/pgs.09.96. PMID: 19891554.
102. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. *Pharmacogenomics*. 2009 Oct;10(10):1687-95. doi:10.2217/pgs.09.125. PMID: 19842940.

103. Tavidou A, Manolopoulos VG. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. *Curr Pharm Des.* 2009;15(27):3167-78. doi: 10.2174/138161209789057968. PMID: 19754389.
104. Manolopoulos VG, Tavidou A. Drugs targeting atherosclerosis: current and emerging approaches. *Curr Pharm Des.* 2009;15(27):3091-3. doi:10.2174/138161209789058039. PMID: 19754383.
105. Tavidou A, Manolopoulos VG. Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369. *Expert Opin Ther Pat.* 2009 Oct;19(10):1473-6. doi:10.1517/13543770903008569. PMID: 19456278.
106. Tavidou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG. Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. *Diabetes Res Clin Pract.* 2009 May;84(2):132-7. doi:10.1016/j.diabres.2009.02.022. PMID: 19324445.
107. Stakos DA, Tavidou A, Margaritis D, Tziakas DN, Kotsianidis I, Chalikias GK, Tsatalas K, Bourikas G, Manolopoulos VG, Boudoulas H. Oxidised low-density lipoprotein and arterial function in beta-thalassemia major. *Eur J Haematol.* 2009 Jun;82(6):477-83. doi: 10.1111/j.1600-0609.2009.01236.x. PMID: 19220416.
108. Ragia G, Arvanitidis KI, Tavidou A, Manolopoulos VG. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19\*17 discovery: the case of Greece. *Pharmacogenomics.* 2009 Jan;10(1):43-9. doi: 10.2217/14622416.10.1.43. PMID: 19102714.
109. Tavidou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. *J Cardiovasc Pharmacol.* 2008 Jun;51(6):573-80. doi: 10.1097/FJC.0b013e31817885fe. PMID: 18520953.
110. Tavidou A, Manolopoulos VG. Novel molecules targeting dyslipidemia and atherosclerosis. *Curr Med Chem.* 2008;15(8):792-802. doi: 10.2174/092986708783955482. PMID: 18393849.
111. Iordanidou M, Tavidou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V, Bougioukas G, Manolopoulos VG. The -759C/T polymorphism of the 5-HT<sub>2C</sub> receptor is associated with type 2 diabetes in male and female Caucasians. *Pharmacogenet Genomics.* 2008 Feb;18(2):153-9. doi:10.1097/FPC.0b013e3282f4ae93. PMID: 18192901.



112. Tavidou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate endothelial nitric oxide synthase expression in cultured endothelial cells. *Endothelium*. 2007 Jul-Oct;14(4-5):239-43. doi: 10.1080/10623320701547216. PMID: 17922341.
113. Tavidou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. *J Pharmacol Exp Ther*. 2007 Dec;323(3):794-804. doi: 10.1124/jpet.107.126375. PMID: 17804677.
114. Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavidou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. *Fundam Clin Pharmacol*. 2007 Aug;21(4):419-26. doi: 10.1111/j.1472-8206.2007.00510.x. PMID: 17635181.
115. Llerena A, Michel G, Jeannesson E, Wong S, Manolopoulos VG, Hockett RD, Boubekeur K, Siest G, Beaune P, Haefliger C, Arnold HP, Junien C, Petrovic N, Molloy R, Bekers O, Donnelly C, Arens HJ, Kaput J, McComb J. Third Santorini conference pharmacogenomics workshop report: "Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?". *Clin Chem Lab Med*. 2007;45(7):843-50. doi:10.1515/CCLM.2007.182. PMID: 17617025.
116. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. *Clin Chem Lab Med*. 2007;45(7):801-14. doi:10.1515/CCLM.2007.184. PMID: 17617019.
117. Tavidou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, Rekka EA, Kourounakis PN, Charalambous A, Manolopoulos VG. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. *Eur J Pharmacol*. 2006 Mar 27;535(1-3):34-42. doi: 10.1016/j.ejphar.2006.02.006. PMID:16545796.
118. Tentes AA, Markakidis SK, Karanikiotis C, Fiska A, Tentes IK, Manolopoulos VG, Dimitriou T. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer. *Langenbecks Arch Surg*. 2006 Apr;391(2):124-9. doi:10.1007/s00423-006-0022-z. Epub 2006 Mar 14. PMID: 16534653.
119. Gurwitz D, Lunshof JE, Dedoussis G, Flordellis CS, Fuhr U, Kirchheiner J, Licinio J, Llerena A, Manolopoulos VG, Sheffield LJ, Siest G, Torricelli F, Vasiliou V, Wong S. Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

Pharmacogenomics J. 2005;5(4):221-5. doi:10.1038/sj.tpj.6500312.  
PMID: 15852053.

120. Tavridou A, Manolopoulos VG. Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. *Eur J Pharmacol.* 2004 Nov 28;505(1-3):213-21. doi: 10.1016/j.ejphar.2004.10.047. PMID:15556155.
121. Tavridou A, Manolopoulos VG. Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes. *Pharmacology.* 2005 Feb;73(2):102-5. doi: 10.1159/000081630. Epub 2004 Oct 19. PMID: 15499225.
122. Papadimitriou E, Waters CR, Manolopoulos VG, Unsworth BR, Maragoudakis ME, Lelkes PL. Regulation of extracellular matrix remodeling and MMP-2 activation in cultured rat adrenal medullary endothelial cells. *Endothelium.* 2001;8(3):181-94. doi: 10.1080/10623320109051564. PMID: 11824471.
123. Manolopoulos VG, Liekens S, Koolwijk P, Voets T, Peters E, Droogmans G, Lelkes PI, De Clercq E, Nilius B. Inhibition of angiogenesis by blockers of volume-regulated anion channels. *Gen Pharmacol.* 2000 Feb;34(2):107-16. doi:10.1016/s0306-3623(00)00052-5. PMID: 10974418.
124. Suh SH, Vennekens R, Manolopoulos VG, Freichel M, Schweig U, Prenen J, Flockerzi V, Droogmans G, Nilius B. Characterisation of explanted endothelial cells from mouse aorta: electrophysiology and Ca<sup>2+</sup> signalling. *Pflugers Arch.* 1999 Oct;438(5):612-20. doi: 10.1007/s004249900085. PMID: 10555557.
125. Mountian I, Manolopoulos VG, De Smedt H, Parys JB, Missiaen L, Wuytack F. Expression patterns of sarco/endoplasmic reticulum Ca<sup>2+</sup>-ATPase and inositol 1,4,5-trisphosphate receptor isoforms in vascular endothelial cells. *Cell Calcium.* 1999 May;25(5):371-80. doi: 10.1054/ceca.1999.0034. PMID: 10463101.
126. Voets T, Manolopoulos V, Eggermont J, Ellory C, Droogmans G, Nilius B. Regulation of a swelling-activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins. *J Physiol.* 1998 Jan 15;506 (Pt 2):341-52. doi: 10.1111/j.1469-7793.1998.341bw.x. PMID: 9490863.
127. Manolopoulos VG, Voets T, Declercq PE, Droogmans G, Nilius B. Swelling-activated efflux of taurine and other organic osmolytes in endothelial cells. *Am J Physiol.* 1997 Jul;273(1 Pt 1):C214-22. doi: 10.1152/ajpcell.1997.273.1.C214. PMID: 9252459.

128. Manolopoulos VG, Fenton JW 2nd, Lelkes PI. The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein. *Biochim Biophys Acta*. 1997 May 27;1356(3):321-32. doi: 10.1016/s0167-4889(97)00002-5. PMID: 9194575.
129. Papadimitriou E, Manolopoulos VG, Hayman GT, Maragoudakis ME, Unsworth BR, Fenton JW 2nd, Lelkes PI. Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. *Am J Physiol*. 1997 Apr;272(4 Pt 1):C1112-22. doi: 10.1152/ajpcell.1997.272.4.C1112. PMID: 9142835.
130. Manolopoulos VG, Droogmans G, Nilius B. Hypotonicity and thrombin activate taurine efflux in BC3H1 and C2C12 myoblasts that is down regulated during differentiation. *Biochem Biophys Res Commun*. 1997 Mar 6;232(1):74-9. doi:10.1006/bbrc.1997.6222. PMID: 9125155.
131. Nilius B, Eggermont J, Voets T, Buyse G, Manolopoulos V, Droogmans G. Properties of volume-regulated anion channels in mammalian cells. *Prog Biophys Mol Biol*. 1997;68(1):69-119. doi: 10.1016/s0079-6107(97)00021-7. PMID: 9481145.
132. Efthimiopoulos S, Punj S, Manolopoulos V, Pangalos M, Wang GP, Refolo LM, Robakis NK. Intracellular cyclic AMP inhibits constitutive and phorbol ester-stimulated secretory cleavage of amyloid precursor protein. *J Neurochem*. 1996 Aug;67(2):872-5. doi: 10.1046/j.1471-4159.1996.67020872.x. PMID: 8764618.
133. Silverman MD, Manolopoulos VG, Unsworth BR, Lelkes PI. Tissue factor expression is differentially modulated by cyclic mechanical strain in various human endothelial cells. *Blood Coagul Fibrinolysis*. 1996 Apr;7(3):281-8. doi:10.1097/00001721-199604000-00001. PMID: 8735134.
134. Manolopoulos VG, Samet MM, Lelkes PI. Regulation of the adenylyl cyclase signaling system in various types of cultured endothelial cells. *J Cell Biochem*. 1995 Apr;57(4):590-8. doi: 10.1002/jcb.240570403. PMID: 7542252.
135. Manolopoulos VG, Liu J, Unsworth BR, Lelkes PI. Adenylyl cyclase isoforms are differentially expressed in primary cultures of endothelial cells and whole tissue homogenates from various rat tissues. *Biochem Biophys Res Commun*. 1995 Mar 8;208(1):323-31. doi: 10.1006/bbrc.1995.1341. PMID: 7887946.
136. Manolopoulos VG, Lelkes PI. Cyclic strain and forskolin differentially induce cAMP production in phenotypically diverse endothelial cells. *Biochem Biophys Res Commun*. 1993 Mar 1;191(3):1379-85. doi: 10.1006/bbrc.1993.1370. PMID: 8385452.

137. Synetos D, Manolopoulos VG, Atlas D, Pipili-Synetos E. Human plasma-derived material with clonidine displacing substance (CDS)-like properties contracts the isolated rat aorta. *J Auton Pharmacol.* 1991 Dec;11(6):343-51. doi:10.1111/j.1474-8673.1991.tb00258.x. PMID: 1684793.
138. Manolopoulos VG, Pipili-Synetos E, Den Hertog A, Nelemans A. Inositol phosphates formed in rat aorta after alpha 1-adrenoceptor stimulation are inhibited by forskolin. *Eur J Pharmacol.* 1991 May 25;207(1):29-36. doi:10.1016/s0922-4106(05)80034-3. PMID: 1680720.
139. Pipili E, Manolopoulos VG, Catravas JD, Maragoudakis ME. Angiotensin converting enzyme activity is present in the endothelium-denuded aorta. *Br J Pharmacol.* 1989 Oct;98(2):333-5. doi: 10.1111/j.1476-5381.1989.tb12599.x. PMID: 2555007; PMCID: PMC1854739.

Projects

## RESEARCH ACTIVITIES

### MAJOR RESEARCH INTERESTS

- Pharmacogenomics and Pharmacoeepigenomics
- Genomics of atherosclerosis, atrial fibrillation, heart failure, diabetes
- Clinical pharmacology and Precision Medicine in different fields of medicine
- Cardiovascular pharmacotherapy

### MAJOR RESEARCH GRANTS

- Action "Supporting Regional Excellence", financed by the Operational Program "Competitiveness, Entrepreneurship and Innovation" within the framework of the NSRF 2014 -2020, co-financed by Greece and the European Union (European Regional Development Fund), Project "Creation of a Center of Excellence for Pharmacological Studies and Precision Medicine" (MIS 5047189, funding 2.740.427,50€, duration 11/2020-09/2023). I was the PI of the project and director of the Center that was implemented within the infrastructure of Laboratory of Pharmacology, DUTH.
- «Collaborative project HEALTH-2007-2.4.2-7: Integrating pharmacogenomic approaches into the treatment of cardiovascular disease», 7<sup>th</sup> Framework Program for Research. European clinical study "European Pharmacogenomics of Anticoagulant Therapy (EU-PACT)" (total funding: 3.000.000 €, 295.000 € for Greece, duration 2008-2013). I was the PI of acenocoumarol arm and national co-ordinator of the study.
- THALIS Programme / General Secretariat for Research and Technology: "Hydrogen Sulfide (H<sub>2</sub>S) a new endogenous regulator of angiogenesis: signaling, physiology/ patho-physiology and development of pharmacological inhibitors" (2013-2015, total budget 521.000 €).

- Technogenesis: Regional Innovative. Actions Programme of East Macedonia and Thrace: “Center for health services on Genomics-Pharmacogenetics” (2006, total budget 80.000 €)

### **PARTICIPATION IN INTERNATIONAL CONSORTIA**

- Online Pharmacogenomics & Personalized Medicine Course Consortium (Erasmus+ action, 2021-2024)
- Vascular Endothelial Growth Factor Consortium (**VEGF**)  
Coordinator: Prof Sophie Siest, Nancy, France
- European Pharmacogenetics Implementation Consortium (**Eu-PIC**), Coordinator: Prof Ron van Schaik, Rotterdam, the Netherlands
- Pharmacogenetics in Childhood Asthma Consortium (**PICA**), Coordinator: Prof Anke-Hilse Maitland van der Zee, Utrecht, the Netherlands
- Clinical Pharmacogenetics Implementation Consortium (**CPIC**), USA-based guideline development platform of PharmGKB

### **OTHER SCIENTIFIC ACTIVITIES**

- Invited speaker in more than 70 national and international congresses.
- Participant in more than 20 election boards for the election & promotion of professors of pharmacology and other specialties in the Medical Department, DUTH.
- Participated in election boards for the election & promotion of professors of pharmacology in the Universities of Thessaloniki (6), Ioannina (2), Patras (6), Larissa (3), Crete (2), and Athens (6).
- Participating in the General Assembly and in other board committees of the Department of Medicine, DUTH.
- Member of the scientific or of the organizing committee in more than 15 national and international congresses in Greece and abroad
- Reviewing 15-20 manuscripts that are submitter for publication in the peer reviewed journals Pharmacogenomics, Pharmacogenomics Journal, Pharmacogenetics and Genomics, Atherosclerosis, Human Genetics, Human Genomics, British Journal of Pharmacology, British Journal of Clinical Pharmacology, The Lancet, Molecular Psychiatry, Drug Metabolism and Drug Interactions, PLOS One, Personalized Medicine, Cell Calcium, Journal of Biochemistry, Molecular Biology and other.
- Evaluator of research proposals for the General Secretariat of Research and Technology, Education Ministry of Romania (2011), Wellcome Trust Foundation (UK, 2012), and the national research committee of Singapore (2019).
- Participated 7 times after invitation as an Evaluator in reviewing research proposals submitted to the European Union in the Framework of HORIZON and 7<sup>th</sup> Framework Program (FP7).
- Was an invited member of the scientific endorsement panel of the European Science Foundation (ESF) ‘Big Pictures’ workshop “Forward Look on Personalised Medicine for the European Citizen – towards more precise medicine for the diagnosis, treatment and

prevention of disease (iPM)”, Dubrovnik, Croatia 13-14 Feb, 2012

- Was an invited member of the endorsement panel of ESF Forward Look Stakeholder Conference on “Personalised Medicine for European Citizen”, 18 April 2012, Rome, Italy.
- Was invited to PHGEN II (Public Health Genomics II) Consortium Endorsement Panel and Final Conference, 19-20 April 2012, Rome, Italy.
- Participated in the official delegation of EU Research Unit who visited **New Zealand** at **24/02-02/03/2008** to meet and discuss with local researchers for topics on education and research, visiting all Faculties of Medicine in the country, as well as other biomedical research institutes in Auckland, Dunedin, Christchurch and Wellington, and giving lectures aiming to promote the scientific relationships between European countries and New Zealand.

#### Memberships

#### **BOARDS/ COMMITTEES (national/ international)**

- **European Society for Pharmacogenomics and Personalized Therapy (ESPT)**, President (2020-2022), President-elect (2016-2020)
- **Greek Society of Basic and Clinical Pharmacology**: Vice-President (2021-2023), President (2017-2021), Vice-President (2015-2017), Gen. Secretary (2013-2015). Elected in board since 2003.
- **European Association for Clinical Pharmacology and Therapeutics (EACPT)**: Executive board member (2019-2021) Representative of Greece (2005-2011 & 2018-2022).
- **Hellenic National Academic Recognition and Information Center (DOATAP)**: Repl. member (2020-2023)

#### **MEMBER OF SCIENTIFIC AND ETHICS COMMITTEES**

Member (current or ex) of several committees of the Academic General Hospital of Evros (Scientific Council, Drug Committee, Ethics committee)

- Repl. Member of Research Committee, DUTH
- Member of **Scientific Board, Committee of Postgraduate Studies and Committee of Programme of Studies**, Medical School, DUTH
- Member of **Drug Committee** of University Hospital of Alexandroupolis
- Member of **Scientific Council** (2005 - 2015)
- Member (2005-2015) of **Ethics Committee (Evaluation of Clinical Protocols)** of University Hospital of Alexandroupolis (President, 2011-2015)
- Member of the **Internal Evaluation Committee** of University Hospital of Alexandroupolis (2008-2009).

#### **EDITORIAL BOARD POSITIONS**

1. Drug Metabolism and Personalized Therapy (Associate Chief Editor)

2. British Journal of Clinical Pharmacology
3. European Journal of Clinical Pharmacology
4. Frontiers, section on Pharmacogenetics & Pharmacogenomics
5. Pharmacogenomics

Other Relevant Information